Clinical trials: Schnitzler Syndrome
Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
The primary goal of the study is to assess the efficacy and safety of RPH-104 in subjects with Schnitzler Syndrome using Schnitzler Disease Activity Score (SDAS), which includes the Physician's Global Assessment (PGA) and the…
- Trial name
- NCT04213274
- Testing
- 80 mg RPH-104
- Where
- 4 sites in United States
- Sponsor
- R-Pharm Overseas, Inc.
Autoinflammatory Syndromes, HIDS
The Efficacy and Safety of ITF2357 in AIS
Autoinflammatory syndromes (AIS) are a group of disorders characterized by recurrent episodes of inflammation.Although for the hereditary autoinflammatory diseases the genetic mutations are known it remains largely unclear how…
- Conditions
- Autoinflammatory Syndromes, HIDS, TRAPS, Schnitzler's Syndrome
- Trial name
- NCT00442182
- Testing
- ITF2357
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Muckle-Wells Syndrome, Schnitzler Syndrome
Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)
This is a single-center open label study of the IL-1 transfusion protein rilonacept in subjects with Muckle-Wells syndrome (MWS), or Schnitzler syndrome (SchS) in Germany.
- Trial name
- ACCILTRA1 (NCT01045772)
- Testing
- rilonacept
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Charite University, Berlin, Germany
Schnitzler Syndrome
A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome
The aim of this study is to assess the effectiveness and safety of Ilaris (canakinumab) in clinical use in patients with Schnitzler's syndrome.
- Trial name
- NCT07598422
- Where
- 5 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Schnitzler Syndrome
Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors
The Schnitzler syndrome is a rare entity characterized by an urticarial rash and recurrent fever in a patient with a monoclonal IgM component.
- Trial name
- NCT00933296
- Where
- 17 sites in France, Italy
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Schnitzler Syndrome
Ilaris® Effects in Schnitzler Syndrome (ILESCH)
This is a multi-center double-blind placebo-controlled study to assess the efficacy and safety of canakinumab (trade name Ilaris®), a high-affinity monoclonal antibody that neutralizes IL-1β, in patients with Schnitzler syndrome.
- Trial name
- ILESCH (NCT01390350)
- Testing
- Canakinumab
- Where
- 5 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Charite University, Berlin, Germany
Hereditary Autoinflammatory Diseases, Schnitzler Syndrome
AutoInflammatory Disease Alliance Registry (AIDA)
Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system.
- Conditions
- Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome
- Trial name
- AIDA (NCT05200715)
- Testing
- No intervention is foreseen by the protocol.
- Where
- 112 sites in Algeria, Australia and 20 more
- Volunteers
- 3,500 people
- Sponsor
- University of Siena
Schnitzler Syndrome
Ilaris (Canakinumab) in the Schnitzler Syndrome
Schnitzler syndrome: Schnitzler syndrome is a rare disabling autoinflammatory syndrome characterized by a chronic urticarial rash and monoclonal gammopathy, accompanied by intermittent fever, arthralgia or arthritis or bone pain.
- Trial name
- NCT01245127
- Testing
- Ilaris
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Schnitzler Syndrome
Efficacy and Safety of Canakinumab in Schnitzler Syndrome
Schnitzler syndrome is a disabling inflammatory disease, characterized by chronic urticaria, fever, arthralgia, bone pain and gammopathy, which can so far only be effectively treated with anakinra, an interleukin-1 receptor…
- Trial name
- NCT01276522
- Testing
- Canakinumab
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Radboud University Medical Center
Schnitzler Syndrome
Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome
This is a pilot, open-label Phase 2, single-center, repeat dose, single cohort, proof-of-concept, safety, pharmacodynamics and efficacy study of dapansutrile capsules to be conducted in subjects with Schnitzler's syndrome (SchS)…
- Trial name
- NCT03595371
- Testing
- dapansutrile
- Where
- Netherlands
- Volunteers
- 2 people
- Sponsor
- Olatec Therapeutics, Inc.
Schnitzler's Syndrome
Tocilizumab in Patients With Schnitzler's Syndrome
Schnitzler's Syndrome (SchS) is a late-onset multifactorial autoinflammatory disease characterized by chronic urticarial skin lesions and a monoclonal gammopathy usually belonging to the immunoglobulin M (IgM) or IgG class.
- Trial name
- TOCISCH (NCT03046381)
- Testing
- Tocilizumab
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Karoline Krause